Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis

被引:406
作者
Stratmann, A
Risau, W
Plate, KH
机构
[1] Univ Freiburg, Neurozentrum, Sch Med, Dept Neuropathol, D-79106 Freiburg, Germany
[2] Max Planck Inst Physiol & Clin Res, Dept Mol Cell Biol, D-6350 Bad Nauheim, Germany
关键词
D O I
10.1016/S0002-9440(10)65733-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Glioblastomas are highly vascular tumors which overexpress the angiogenesis factor vascular endothelial growth factor (VEGF), VEGF and its receptors, VEGF-R1 and VEGF-R2, have been shown to be necessary for embryonic angiogenesis as well as for turner angiogenesis. Recently, the angiopoietin/Tie2 receptor system has been shown to exert functions in the cardiovascular system that are distinct from VEGF but are also critical for normal vascular development. To assess the potential role of Tie2 and its ligands angiopoietin-1 and angiopoietin-2 in tumor vascularization, we analyzed their expression pattern in human gliomas, Tie-2 was up-regulated in tumor endothelium compared to normal human brain tissue. We further observed cell type-specific up-regulation of the message for both angiopoietin-1 and angiopoietin-2 in gliomas, Whereas Ang-1 mRNA was expressed in tumor cells, Ang-2 mRNA was detected in endothelial cells of a subset of glioblastoma blood vessels. Small capillaries with few periendothelial support cells showed strong expression of Angiopoietin-2, whereas larger glioblastoma vessels with many periendothelial support cells showed little or no expression. Although the function of Tie2 and its ligands in tumor angiogenesis remains a subject of speculation, our findings are in agreement with a recently proposed hypothesis that in the presence of VEGF, local production of Ang-2 might promote angiogenesis.
引用
收藏
页码:1459 / 1466
页数:8
相关论文
共 47 条
[1]  
Borgstrom P, 1996, CANCER RES, V56, P4032
[2]  
BREM S, 1972, J NATL CANCER I, V48, P347
[3]   Role of tissue factor in embryonic blood vessel development [J].
Carmeliet, P ;
Mackman, N ;
Moons, L ;
Luther, T ;
Gressens, P ;
VanVlaenderen, I ;
Demunck, H ;
Kasper, M ;
Breier, G ;
Evrard, P ;
Muller, M ;
Risau, W ;
Edgington, T ;
Collen, D .
NATURE, 1996, 383 (6595) :73-75
[4]   Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor [J].
Cheng, SY ;
Huang, HJS ;
Nagane, M ;
Ji, XD ;
Wang, DG ;
Shih, CCY ;
Arap, W ;
Huang, CM ;
Cavenee, WK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) :8502-8507
[5]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[6]   Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [J].
Davis, S ;
Aldrich, TH ;
Jones, PF ;
Acheson, A ;
Compton, DL ;
Jain, V ;
Ryan, TE ;
Bruno, J ;
Radziejewski, C ;
Maisonpierre, PC ;
Yancopoulos, GD .
CELL, 1996, 87 (07) :1161-1169
[7]  
DUMONT DJ, 1992, ONCOGENE, V7, P1471
[8]   DOMINANT-NEGATIVE AND TARGETED NULL MUTATIONS IN THE ENDOTHELIAL RECEPTOR TYROSINE KINASE, TEK, REVEAL A CRITICAL ROLE IN VASCULOGENESIS OF THE EMBRYO [J].
DUMONT, DJ ;
GRADWOHL, G ;
FONG, GH ;
PURI, MC ;
GERTSENSTEIN, M ;
AUERBACH, A ;
BREITMAN, ML .
GENES & DEVELOPMENT, 1994, 8 (16) :1897-1909
[9]   Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia [J].
Enholm, B ;
Paavonen, K ;
Ristimaki, A ;
Kumar, V ;
Gunji, Y ;
Klefstrom, J ;
Kivinen, L ;
Laiho, M ;
Olofsson, B ;
Joukov, V ;
Eriksson, U ;
Alitalo, K .
ONCOGENE, 1997, 14 (20) :2475-2483
[10]   Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442